Ellims P H, Eng Gan T, Medley G, Van Der Weyden M B
Blood. 1981 Nov;58(5):926-30.
To determine whether kinase (TK) isozyme status adds clinically useful information in adult non-Hodgkin's lymphoma (NHL), we have analyzed peripheral blood plasma and lymphocytes of 44 patients with NHL for either TK1 or TK2 isozyme activity. On the basis of isozyme status, patients could be divided into two groups that did not differ significantly with respect to known determinants for survival. The median survival of patients exhibiting peripheral blood TK1 thymidine kinase activity was 40 wk and that of individuals with TK2 activity was in excess of 200 wk. These data suggest that peripheral blood TK1 isozyme is a useful independent biochemical marker for a subgroup of NHL who respond poorly to current therapy and thus require new therapeutic approaches.
为了确定激酶（TK）同工酶状态是否能为成人非霍奇金淋巴瘤（NHL）提供临床有用信息，我们分析了44例NHL患者外周血血浆和淋巴细胞中的TK1或TK2同工酶活性。根据同工酶状态，患者可分为两组，这两组在已知的生存决定因素方面无显著差异。外周血显示TK1胸苷激酶活性的患者中位生存期为40周，而具有TK2活性的个体中位生存期超过200周。这些数据表明，外周血TK1同工酶是NHL亚组的一种有用的独立生化标志物，该亚组对当前治疗反应不佳，因此需要新的治疗方法。
